{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"4.2","value":"1.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"doxorubicin hydrochloride: given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.\n\ngemcitabine hydrochloride: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle","id":"OG000","title":"Gemcitabine+Doxorubicin"}],"paramType":"MEDIAN","populationDescription":"Only patients who had re-staging scans are included in the number of participants analyzed.","reportingStatus":"POSTED","timeFrame":"Through the end of follow up, for an average of 8 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}